Erratum to: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells
Authors:
Xing-dong Xu, Lan Yang, Li-yun Zheng, Yan-yan Pan, Zhi-fei Cao, Zhi-qing Zhang, Quan-sheng Zhou, Bo Yang, Cong Cao
Unfortunately, the original version of this article [1] contained an error within Fig. 5. For testing Sema4D protein expression in PaTu8988 cells with/out SAHA treatment, the protein samples of Fig. 2D were re-tested by Western blot assay using Sema4D antibody (Fig. 5E). The correct version of Fig. 5E can be found below. This does not alter the conclusion of the result.
Erratum to: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells
Authors
Xing-dong Xu Lan Yang Li-yun Zheng Yan-yan Pan Zhi-fei Cao Zhi-qing Zhang Quan-sheng Zhou Bo Yang Cong Cao
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.